Skip to main content

Table 2 Participant characteristics stratified by severity of balance disturbance

From: Cannabis use is not associated with increased balance disturbances in HIV-infected individuals

Variables Moderate-severe Imbalance (n = 430) No or minimal Imbalances (n = 3191) Effect size (95% CI) p value
Demographics
 Age (years), mean (SD) 51.7 (10) 44.8 (11) 0.62 [0.52; 0.72]a < .0001
 Education, mean (SD) 12.9 (3) 13.0 (3) − 0.03 [− 0.13; 0.06]a 0.756
 Male, n (%) 306 (71.2) 2504 (78.5) 0.67 [0.54; 0.84]b < .0006
 Ethnicity, n (%)
  Hispanic 54 (12.6) 590 (18.5)   0.04
  Non-Latino white 216 (50.2) 1524 (47.8)  
  African American 144 (33.5) 949 (29.7)  
  Asian 4 (0.9) 33 (1.0)  
  Other 12 (2.8) 95 (3.0)  
 BMI (kg/m2), mean (SD) 27.9 (7) 26.9 (9) 0.10 [0.00; 0.20]a 0.006
Cannabis use, n (%)
 Urine toxicology positive for THC 63 (14.9) 451 (14.27) 1.09 [0.82; 1.46]b 0.5
 Cannabis ever used, n (%) 262 (73.8) 1964 (74.4) 1.03 [0.80; 1.32]b 0.8
 Lifetime years Cannabis use, mean (SD) 9.7 (7.8) 8.4 (6.8) 0.12 [− 0.00; 0.25]a 0.07
 Lifetime Quantity Cannabis (grams), mean (SD) 4871 (11573) 4648 (12705) 0.11 [0.01; 0.14]a 0.3
HIV serostatus, n (%)
 HIV+ individuals 384 (13.5) 2462 (86.5)   
 HIV− individuals 42 (5.5) 717 (94.6)   
Neurological disease, n (%)
 cDSPN, n (%) 303(70.5) 1469 (46.0) 2.79 [2.24; 3.47]b < .0001
 gait ataxia, n (%) 54 (12.5) 96 (3.0) 0.2 [0.15; 0.30]b < .0001
Medication currently used, n (%)
 Opioids, n (%) 132 (30.7) 401 (12.6) 3.08 [2.44; 3.87]b < .0001
 Sedatives, n (%) 77 (17.9) 327 (10.2) 1.99 [1.51; 2.62]b < .0001
 Antihypertensives, n (%) 52 (12.1) 235 (7.4) 1.77 [1.29; 2.44]b < .0001
  1. Effect size presented as aCohen’s d or bodds ratios
  2. CI confidence interval, BMI body mass index, cDSPN chronic distal sensory polyneuropathy